These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35122060)

  • 1. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial.
    Parikh AR; Szabolcs A; Allen JN; Clark JW; Wo JY; Raabe M; Thel H; Hoyos D; Mehta A; Arshad S; Lieb DJ; Drapek LC; Blaszkowsky LS; Giantonio BJ; Weekes CD; Zhu AX; Goyal L; Nipp RD; Dubois JS; Van Seventer EE; Foreman BE; Matlack LE; Ly L; Meurer JA; Hacohen N; Ryan DP; Yeap BY; Corcoran RB; Greenbaum BD; Ting DT; Hong TS
    Nat Cancer; 2021 Nov; 2(11):1124-1135. PubMed ID: 35122060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma.
    Christensen TD; Maag E; Theile S; Madsen K; Lindgaard SC; Hasselby JP; Nielsen DL; Johansen JS; Chen IM
    ESMO Open; 2024 Jun; 9(6):103489. PubMed ID: 38838501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial.
    Saunders MP; Graham J; Cunningham D; Plummer R; Church D; Kerr R; Cook S; Zheng S; La Thangue N; Kerr D
    ESMO Open; 2022 Dec; 7(6):100594. PubMed ID: 36327756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for pancreatic ductal adenocarcinoma.
    Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
    J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
    Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
    Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.
    Parseghian CM; Patnana M; Bhosale P; Hess KR; Shih YT; Kim B; Kopetz S; Overman MJ; Varadhachary GR; Javle M; Naing A; Piha-Paul S; Hong D; Le H; Subbiah V; Pant S
    J Immunother; 2018; 41(6):284-291. PubMed ID: 29668571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer.
    Wu C; Shao Y; Gu W
    Clin Transl Oncol; 2023 Jul; 25(7):1916-1928. PubMed ID: 36717514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
    Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
    JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
    Xie C; Duffy AG; Brar G; Fioravanti S; Mabry-Hrones D; Walker M; Bonilla CM; Wood BJ; Citrin DE; Gil Ramirez EM; Escorcia FE; Redd B; Hernandez JM; Davis JL; Gasmi B; Kleiner D; Steinberg SM; Jones JC; Greten TF
    Clin Cancer Res; 2020 May; 26(10):2318-2326. PubMed ID: 31996388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
    Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36634920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
    Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma.
    Piper M; Van Court B; Mueller A; Watanabe S; Bickett T; Bhatia S; Darragh LB; Mayeda M; Nguyen D; Gadwa J; Knitz M; Corbo S; Morgan R; Lee JJ; Dent A; Goodman K; Messersmith W; Schulick R; Del Chiaro M; Zhu Y; Kedl RM; Lenz L; Karam SD
    Clin Cancer Res; 2022 Mar; 28(5):1013-1026. PubMed ID: 34862244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
    Ye C; Zheng L; Yuan CH
    Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
    Tan E; El-Rayes B
    J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.